Skip to content
vigabatrin.org

Vigabatrin FAQ

On this page

These are the questions parents and patients ask most about vigabatrin. Each short answer below links to a page with the full detail and sources. Vigabatrin comes as 500 mg tablets, 500 mg powder packets mixed with water, and a ready-to-use liquid for babies with infantile spasms. Every form carries the same warning about permanent vision loss.1,2,3

Forms and preparation

Vigafyde, the ready-to-use liquid, was approved by the FDA in June 2024.4 It is 100 mg per mL, needs no mixing, is kept for up to 90 days after opening, and is labeled only for infantile spasms from 1 month to 2 years. It can be given by mouth or through a G-tube; with a GJ tube, use the G-port and flush with water afterward.3

Each 500 mg powder packet is dissolved in 10 mL of water, making 50 mg per mL. Each dose is prepared and used right away, and any unused portion is thrown away.2,5 A 2025 lab study by authors from a generic maker found mixed powder stayed within potency limits for 48 hours in the fridge in apple juice, whole milk or infant formula; the labels still say water only.6

We found no study of splitting or crushing vigabatrin tablets. In a review of 13 studies of other split tablets, splitting was satisfactory in only 55% of cases,7 and in a study of manipulated hydrocortisone tablets, first-time users got only 57 to 58% of doses within 20% of target.8 NIOSH says crushing tablets increases the potential for exposure of workers.9

Vigabatrin is on the NIOSH hazardous-drug list, flagged only as a developmental or reproductive hazard.10 NIOSH and USP handling guidance is written for healthcare workers and settings, not families.9,11

Dosing, timing and stopping

The dosage guide gives doses by weight in mg and mL, kidney adjustments and how to switch forms. Babies who respond to vigabatrin for infantile spasms usually do so within days; in a 23-center US cohort the median was 3 days.12 The label advises withdrawing vigabatrin for infantile spasms if it has not clearly helped within 2 to 4 weeks.1

The labels say not to stop vigabatrin suddenly. "As with all AEDs, vigabatrin should be withdrawn gradually to minimize increased seizure frequency."1 In the infantile spasms study, the dose was lowered by 25 to 50 mg/kg every 3 to 4 days.3

Side effects and vision

The boxed warning is about permanent vision loss. Based on adult studies, 30 percent or more of patients can be affected. Vision is checked at baseline (no later than 4 weeks after starting), at least every 3 months during treatment, and about 3 to 6 months after stopping.1 The risk rises with dose and total exposure, and no dose is known to be risk-free.3 For infants, who cannot do the field tests adults do, eye specialists can use other methods such as electroretinography (ERG).13

Common side effects in infants are sleepiness and irritability; in adults, drowsiness, dizziness, headache and fatigue.14 In the label's pooled pediatric trials, 47% of children on vigabatrin gained at least 7% of their body weight, against 19% on placebo.3 Against carbamazepine, weight gain was 11% vs 5%.15

The taurine idea comes from a review of possible causes of the vision loss, not from a treatment trial.16

How it works

Vigabatrin's anti-seizure effect is believed to come from irreversibly blocking GABA transaminase, which raises GABA levels in the central nervous system.1,17 Its action long outlasts its presence in the blood.18

Conditions

For most infantile spasms, vigabatrin is weighed against hormone treatment. For spasms caused by tuberous sclerosis, guidelines worldwide recommend vigabatrin first,19 and in pooled early reports spasms stopped in 95% of babies with TSC.20 Starting it before seizures is debated: the EPISTOP trial found seizure benefits, while PREVeNT found no benefit for cognition at 24 months.21,22 In older children and adults, vigabatrin is an add-on for refractory complex partial (focal) seizures.1

Brands, cost and access

Vigadrone is a generic vigabatrin powder approved in 2018, and Vigafyde is the only ready-to-use vigabatrin solution in FDA records.23 Vigabatrin is available only through the Vigabatrin REMS, so it is filled by certified pharmacies.3 What you pay depends on insurance, copay programs and package size, and every product is compared on the vigabatrin brands page. The studies behind these answers are listed with links on the sources page.

Common questions

What is VGB?

VGB is a common abbreviation for vigabatrin, used in research papers and clinic notes. Vigabatrin is a seizure medicine sold in the US as Sabril, as the ready-to-use liquid Vigafyde, and as generics such as Vigadrone.

What is the black box warning for vigabatrin?

The boxed warning is about permanent vision loss. Vigabatrin can narrow side vision in both eyes and may also reduce sharpness of vision. Based on adult studies, 30 percent or more of patients can be affected. The risk rises with dose and total exposure, and no dose is known to be risk-free. Vision is checked before or soon after starting, at least every 3 months during treatment, and about 3 to 6 months after stopping.

What signs of vision loss should I watch for in my baby?

The vision loss narrows side vision, and babies cannot do the field tests that adults do, so eye specialists use other methods such as electroretinography. Do not rely on noticing changes yourself. Keep every scheduled eye exam, and tell the doctor about any change you notice in how your baby looks at or follows things.

Is there a ready-to-use vigabatrin liquid?

Yes. Vigafyde, approved by the FDA in June 2024, is a ready-to-use oral solution at 100 mg per mL. It needs no mixing and is kept for up to 90 days after opening. It is labeled only for infantile spasms in babies 1 month to 2 years old.

How do you mix vigabatrin powder?

Empty each 500 mg packet into a clean cup and dissolve it in 10 mL of cold or room-temperature water per packet. That makes 50 mg per mL. Check that it is clear, draw up the prescribed volume with an oral syringe, give it right away and throw away what is left.

Can vigabatrin powder be mixed in juice or milk?

The labels say to mix it with water only and use it immediately. A 2025 lab study by a generic maker found the powder stayed within potency limits for 48 hours in the fridge in apple juice, whole milk or infant formula. That is not label guidance, so ask your pharmacist or prescriber before mixing it with anything other than water.

Can I give the liquid through a G-tube?

The Vigafyde label allows it to be given by mouth or through a gastrostomy (G) tube. With a GJ tube, use the G-port. Flush the tube with water afterward.

Can vigabatrin tablets be crushed or split?

The 500 mg tablet is scored, but we found no study of how evenly vigabatrin tablets split or how much a crushed tablet delivers. Studies of other tablets show hand-splitting is often uneven, and crushing raises exposure to the drug for the person doing it. If a dose cannot be made from whole tablets, ask the prescriber about the powder.

What does vigabatrin do to GABA?

GABA is a chemical messenger that calms nerve activity. Vigabatrin is believed to work by irreversibly blocking GABA transaminase, the enzyme that breaks GABA down, which raises GABA levels in the brain and spinal cord. Because the body has to make new enzyme, the effect lasts longer than the drug stays in the blood.

Why is vigabatrin on the NIOSH hazardous drug list?

NIOSH lists vigabatrin because of possible harm to pregnancy and development; that is its only flagged hazard. The NIOSH and USP handling rules are written for healthcare workers, not families. At home, handle the medicine calmly and cleanly, and ask the pharmacist about handling if someone in the house is pregnant or planning a pregnancy.

What are the most common side effects of vigabatrin?

In infants, sleepiness and irritability are common. In adults, drowsiness, dizziness, headache and fatigue are common, and weight gain can occur. If sleepiness affects feeding or daily life, tell the prescriber rather than changing the dose yourself. Vision loss is the most serious risk and is checked with regular eye exams.

Does vigabatrin cause weight gain?

It can. In the label's pooled pediatric trials, 47 percent of children on vigabatrin gained at least 7 percent of their body weight, against 19 percent on placebo. In a trial against carbamazepine in newly diagnosed epilepsy, weight gain was reported in 11 percent on vigabatrin and 5 percent on carbamazepine.

How long does vigabatrin take to work for infantile spasms?

Often days. In a 23-center US cohort, babies who responded to vigabatrin did so in a median of 3 days, and experts advise reassessing any baby who has not responded within a week. The label advises stopping vigabatrin for infantile spasms if it has not clearly helped within 2 to 4 weeks.

Can vigabatrin be stopped suddenly?

No. The labels say not to stop vigabatrin suddenly: it should be withdrawn gradually to minimize increased seizure frequency. The dose is lowered step by step; in the infantile spasms study it was reduced by 25 to 50 mg/kg every 3 to 4 days. The prescriber sets the plan, and vision is checked again 3 to 6 months after the last dose.

Can vigabatrin be used for tuberous sclerosis complex (TSC)?

Yes. For infantile spasms caused by TSC, guidelines worldwide recommend vigabatrin as a first-line treatment, and spasms stop in most babies. Starting vigabatrin before seizures appear is still debated: one trial found fewer seizures, another found no benefit for development or focal seizures.

Does taurine help prevent vigabatrin vision loss?

A link between vigabatrin vision loss and low taurine is a hypothesis discussed in a review of vigabatrin vision safety, but our sources include no study showing that taurine supplements protect vision in people taking vigabatrin. Do not start a supplement without asking the prescriber.

How much does vigabatrin cost?

It depends on the product, your insurance and the pharmacy, and list prices change, so we do not publish prices. Vigabatrin is filled only by REMS-certified pharmacies. Ask the pharmacy what you will pay, and ask the pharmacy or the product's manufacturer whether a copay program applies.

What is Vigadrone?

Vigadrone is a generic vigabatrin powder for oral solution, approved in 2018. It comes in 500 mg packets and is mixed the same way as Sabril powder. Vigafyde is the only ready-to-use vigabatrin liquid; no generic version of it appears in FDA records.

References

  1. 1.SABRIL (vigabatrin) tablets prescribing information, revised 10/2021. Source
  2. 2.SABRIL (vigabatrin) for oral solution prescribing information, revised 10/2021. Source
  3. 3.VIGAFYDE (vigabatrin) oral solution prescribing information, revised 11/2025. Source
  4. 4.Drugs@FDA (openFDA API): NDA 217684, VIGAFYDE (vigabatrin) oral solution 100 mg/mL, sponsor Pyros Pharms; original approval 2024-06-17. Source
  5. 5.VIGADRONE (vigabatrin) for oral solution, revised 12/2025, Upsher-Smith. Source
  6. 6.Zachman M, Gong L, An L, Halvorsen MB. Dissolution and stability of vigabatrin powder in water, fruit juice, milk, and infant formula. Epilepsy Behav Rep. 2025;31:100816. PMID 40838171 · DOI 10.1016/j.ebr.2025.100816 PubMedDOI
  7. 7.Eserian JK, Lombardo M, Chagas JR, Galduróz JCF. Actual Versus Expected Doses of Half Tablets Containing Prescribed Psychoactive Substances: A Systematic Review. Prim Care Companion CNS Disord. 2018;20(1):17r02211. PMID 29469240 · DOI 10.4088/PCC.17r02211 PubMedDOI
  8. 8.Watson C, Webb EA, Kerr S, et al. How close is the dose? Manipulation of 10 mg hydrocortisone tablets to provide appropriate doses to children. Int J Pharm. 2018;545(1-2):57-63. PMID 29705101 · DOI 10.1016/j.ijpharm.2018.04.054 PubMedDOI
  9. 9.NIOSH. Managing Hazardous Drug Exposures: Information for Healthcare Settings. Hodson L, Ovesen J, Couch J, et al. DHHS (NIOSH) Publication No. 2023-130, April 2023. DOI 10.26616/NIOSHPUB2023130 DOI
  10. 10.NIOSH. NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. Ovesen JL, Sammons D, Connor TH, et al. DHHS (NIOSH) Publication No. 2025-103, December 2024 (supersedes 2016-161). DOI 10.26616/NIOSHPUB2025103 · DOI
  11. 11.USP. USP <800> FAQs, updated January 21, 2026. Source
  12. 12.Yuskaitis CJ, Mytinger JR, Baumer FM, et al. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. Neurology. 2022;99(22):e2494-e2503. PMID 36038267 · DOI 10.1212/WNL.0000000000201232 PubMedDOI
  13. 13.Sergott RC, Westall CA. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand Suppl. 2011;(192):48-56. PMID 22061180 · DOI 10.1111/j.1600-0404.2011.01600.x PubMedDOI
  14. 14.Walker SD, Kälviäinen R. Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand Suppl. 2011;(192):72-82. PMID 22061182 · DOI 10.1111/j.1600-0404.2011.01602.x PubMedDOI
  15. 15.Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet. 1999;354(9172):13-19. PMID 10406359 · DOI 10.1016/s0140-6736(98)10531-710531-7) PubMedDOI
  16. 16.Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl. 2011;(192):57-71. PMID 22061181 · DOI 10.1111/j.1600-0404.2011.01601.x PubMedDOI
  17. 17.Gidal BE, Privitera MD, Sheth RD, et al. Vigabatrin: a novel therapy for seizure disorders. Ann Pharmacother. 1999;33(12):1277-1286. PMID 10630829 · DOI 10.1345/aph.18376 PubMedDOI
  18. 18.Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):267-278. PMID 1395360 · DOI 10.2165/00003088-199223040-00003 PubMedDOI
  19. 19.Erdemir G, Rao CK, Pino AF, et al. Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches. Epilepsia. 2026;67(9):4600-4617. PMID 42274306 · DOI 10.1002/epi.70329 PubMedDOI
  20. 20.Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14(2):71-74. PMID 10073425 · DOI 10.1177/088307389901400201 PubMedDOI
  21. 21.Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2021;89(2):304-314. PMID 33180985 · DOI 10.1002/ana.25956 · NCT02098759 PubMedDOI
  22. 22.Bebin EM, Peters JM, Porter BE, et al. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Ann Neurol. 2024;95(1):15-26 (Epub 2023). PMID 37638552 · DOI 10.1002/ana.26778 · NCT02849457 PubMedDOI
  23. 23.Drugs@FDA (openFDA): numerous ANDAs for vigabatrin for oral solution 500 mg/packet and tablets 500 mg. Examples: VIGADRONE ANDA 210196 (approved 2018-06-21; DailyMed labeler now Upsher-Smith); VIGPODER ANDA 214961 (Pyros; openFDA product: vigabatrin 500MG/PACKET, dosage form "FOR SOLUTION", route oral, TE code AA, i.e. a powder for oral solution; original approval 2022-06-24; no current DailyMed SPL found under the name Vigpoder); Teva, Amneal, Dr. Reddy's, Zydus and others. VIGAFYDE was the only vigabatrin "SOLUTION" (ready-to-use) dosage form in the results. Source

All sources used on this site, with summaries